We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Saliva Test Fast Tracks Heart Attack Diagnosis

By LabMedica International staff writers
Posted on 07 Sep 2020
Heart attacks need urgent diagnosis, followed by treatment to restore blood flow to blocked arteries. More...
Diagnosis is based on symptoms (such as chest pain), an electrocardiogram (ECG) and a blood test for cardiac troponin, a protein released into the blood when the heart muscle is injured.

A saliva test could fast track heart attack diagnosis, according to a preliminary study. The innovative technique requires patients to spit into a tube and provides results in 10 minutes, compared to at least one hour for the standard blood test and saliva collection is a non-invasive.

Medical scientists at the Soroka University Medical Centre (Be’er Sheva, Israel) examined if cardiac troponin could be detected in the saliva of patients with heart muscle injury. Saliva samples underwent a unique processing procedure to remove highly abundant proteins. The processing procedure is called Saliva High Abundant Proteins Effective Depletion (SHAPED). A total of 32 patients with heart muscle injury (i.e. they had a positive cardiac troponin blood test) and 13 healthy volunteers were requested to provide saliva samples by spitting into a collecting tube. Then, half of each sample was processed, and the other half remained in its natural state. They then tested the processed and unprocessed saliva samples for cardiac troponin.

The investigators compared the results from the saliva samples (processed and unprocessed) with the blood samples. There was strong agreement between the blood findings and the processed saliva, but not saliva in its natural state. Most of the processed saliva samples tested were positive for troponin, compared to just 6% of the unprocessed saliva. Of the 25 patients with myocardial injury whose samples had advanced processing, 21 were confirmed positive for MI by both methods (sensitivity, 84.0%). Among healthy participants, no cardiac troponin was detected in the processed and unprocessed saliva samples.

Roi Westreich, MD, A Cardiologist and lead author of the study, said, “Since no test has been developed for use on saliva, we had to use commercially available tests intended for whole blood, plasma, or serum, and adjust them for saliva examination. This early work shows the presence of cardiac troponin in the saliva of patients with myocardial injury. Further studies are needed to determine how long troponin stays in the saliva after a heart attack. In addition, we need to know how many patients would erroneously be diagnosed with heart attack and how many cases would be missed.” The study was presented at the digital European Society of Cardiology 2020 congress held August 29 to September 1, 2020 via Sophia Antipolis, France.

Related Links:
Soroka University Medical Centre


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously (Photo courtesy of OptraSCAN)

New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.